ORTHO-NOVUM 7/14-28
Clinical safety rating
cautionComprehensive clinical and safety monograph for ORTHO-NOVUM 7/14-28 (ORTHO-NOVUM 7/14-28).
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
| Metabolism | Ethinyl estradiol: primarily metabolized via CYP3A4, undergoes first-pass metabolism and enterohepatic circulation. Norethindrone: reduced to metabolites, conjugated (glucuronidation and sulfation), and excreted in urine and feces. |
| Excretion | Renal: ~50-60% (metabolites); biliary/fecal: ~30-40% (metabolites); unchanged drug <1% in urine. |
| Half-life | Ethinyl estradiol: ~13-27 h (mean 17 h); Norethindrone: ~5-14 h (mean 8 h). Clinical context: steady-state achieved after ~5 days; half-life supports daily dosing. |
| Protein binding | Ethinyl estradiol: 97-98% bound to serum albumin; Norethindrone: 97-99% bound to albumin (major) and SHBG (minor). |
| Volume of Distribution | Ethinyl estradiol: 2.3-4.2 L/kg (mean 3.5 L/kg); Norethindrone: 2.5-5.0 L/kg (mean 3.8 L/kg). Clinical meaning: extensive distribution into tissues, including reproductive organs. |
| Bioavailability | Oral: Ethinyl estradiol ~40-48% (first-pass metabolism); Norethindrone ~50-70% (first-pass metabolism). Food may slightly increase bioavailability. |
| Onset of Action | Oral: Pharmacodynamic effect (ovulation suppression) begins within 2-3 days of initiation when started on day 1 of cycle. Contraceptive effect requires 7 days of continuous use if started after day 5. |
| Duration of Action | Oral: Contraceptive effect maintained for the 21-day active pill period; withdrawal bleed occurs during the 7-day placebo interval. Duration of pharmacodynamic effects (e.g., endometrial suppression) persists for the dosing interval. |
| Molecular Weight | 312.45 |
One tablet daily for 28 days; each tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg (days 1-7), norethindrone 0.75 mg and ethinyl estradiol 0.035 mg (days 8-14), norethindrone 1 mg and ethinyl estradiol 0.035 mg (days 15-21), and placebo (days 22-28). Take at same time each day.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended in published literature; however, use with caution in patients with severe renal impairment (eGFR <30 mL/min) due to potential fluid retention and electrolyte disturbances. No data for specific GFR-based modifications. |
| Liver impairment | Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or hepatic tumors. For Child-Pugh class A or B, use with caution; no specific dose adjustment guidelines exist. Discontinue if jaundice or signs of hepatic dysfunction develop. |
| Pediatric use | Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults: one tablet daily for 28 days. Use only after appropriate evaluation and counseling. |
| Geriatric use | Not indicated for use in postmenopausal women. Elderly-specific dosing not applicable. |
| 1st trimester | Contraindicated. Oral contraceptives are not recommended during pregnancy. There is no evidence of teratogenicity from inadvertent use in early pregnancy, but use is contraindicated once pregnancy is confirmed. |
| 2nd trimester | Contraindicated. Continued use is not recommended during the second trimester as pregnancy is established. |
| 3rd trimester | Contraindicated. Use during the third trimester is not recommended due to potential adverse effects on fetal development and maternal health. |
Clinical note
Comprehensive clinical and safety monograph for ORTHO-NOVUM 7/14-28 (ORTHO-NOVUM 7/14-28).
| Placental transfer | Steroid hormones cross the placenta to a limited extent. Active metabolites may affect fetal development, but specific transfer data for ORTHO-NOVUM 7/14-28 is not well-established. |
| Breastfeeding | Oral contraceptives can reduce milk production and pass into breast milk in small amounts. Use is generally not recommended during breastfeeding, especially in the early postpartum period. Alternatives should be considered. |
| Lactation Rating | L4* (Possibly Hazardous - reduced milk production) |
| Teratogenic Risk | First trimester: Post-marketing studies have not shown an increased risk of birth defects with combined oral contraceptives. However, inadvertent use during early pregnancy is not associated with teratogenicity. Second and third trimesters: Use is contraindicated due to potential adverse effects on fetal development, including estrogenic effects on female fetuses and androgenic effects on male fetuses. There is a risk of fetal genital abnormalities if exposed in utero, though absolute risk is low. Overall, category X designation for use during pregnancy. |
| Fetal Monitoring | Monitor blood pressure regularly due to potential hypertensive effects. Assess for signs of thromboembolism, especially in pregnancy or postpartum. Perform pregnancy test before initiation. If accidental use during pregnancy, monitor fetal growth and development via ultrasound. No specific additional fetal monitoring required beyond standard prenatal care. |
| Fertility Effects | Upon discontinuation, fertility typically returns promptly, though some women may experience a temporary delay in ovulation or menstrual regularity. No permanent impairment of fertility has been demonstrated. Long-term use may be associated with a slight delay in return to fertility but no irreversible effects. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events. Women over 35 who smoke should not use this product.
| Serious Effects |
Current or history of thrombophlebitis or thromboembolic disordersCerebrovascular or coronary artery diseaseKnown or suspected breast carcinoma or estrogen-dependent neoplasiaUndiagnosed abnormal genital bleedingPregnancy or suspected pregnancyKnown or suspected carcinoma of the endometriumHepatic adenoma or carcinomaActive liver disease or impaired liver function
| Precautions | Increased risk of thromboembolic disorders (DVT, PE, stroke, MI), Cigarette smoking increases cardiovascular risk, Increased risk of cervical cancer (HPV-related), Hepatic neoplasia (benign/malignant) associated with long-term use, Exacerbation of migraine, Depression, Gallbladder disease, Impaired glucose tolerance, Elevated blood pressure, Hereditary angioedema |
| Food/Dietary | Grapefruit juice may increase ethinyl estradiol levels and risk of adverse effects; consider avoiding. No other significant food interactions. |
| Clinical Pearls | ORTHO-NOVUM 7/14-28 is a triphasic oral contraceptive with variable doses of norethindrone and ethinyl estradiol. Bleeding irregularities are common, especially in the first few cycles; reassure patients if pregnancy is ruled out. Missed pills increase risk of breakthrough ovulation; refer to package instructions for missed doses. Concomitant use of CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) may reduce contraceptive efficacy. |
| Patient Advice | Take one pill daily at the same time, starting on the first Sunday after your period begins. · Use backup contraception (e.g., condoms) for the first 7 days of the first cycle. · If you miss a pill, follow the specific instructions in the package insert based on how many you missed and the week of the cycle. · Common side effects include nausea, breast tenderness, and spotting; these often improve after 2-3 cycles. · Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35 years old. · This medication does not protect against HIV or other sexually transmitted infections. |
Loading safety data…